Summary
Bristol-Myers Squibb Company (BMY) filed this Form 10-Q for the quarterly period ended September 30, 2002, with a significant delay due to a required restatement of previously issued financial statements. This restatement, detailed in Note 2, primarily addresses errors in revenue recognition related to sales incentives offered to U.S. pharmaceutical wholesalers, necessitating a shift to a consignment model for certain transactions. The delay in filing had triggered potential debt acceleration clauses, which were not exercised by creditors. The company is actively addressing material weaknesses identified by its auditors related to financial reporting and oversight. Significant legal proceedings, including antitrust litigation concerning TAXOL® and BUSPAR, are ongoing, with proposed settlements announced. These factors, combined with ongoing investigations by the SEC and U.S. Attorney's Office concerning wholesaler inventory issues, create a complex operating and financial environment for BMY. Investors should closely monitor the resolution of these legal and accounting issues.
Key Highlights
- 1The financial statements for the period ending September 30, 2002, were significantly delayed and required restatement due to accounting errors, primarily related to revenue recognition for certain U.S. pharmaceutical wholesaler sales.
- 2The company implemented a consignment model for specific sales to two major U.S. pharmaceutical wholesalers, impacting revenue recognition timing.
- 3Significant litigation continues, notably antitrust cases related to TAXOL® and BUSPAR, with proposed settlements announced, totaling hundreds of millions of dollars.
- 4Bristol-Myers Squibb identified and is addressing two 'material weaknesses' in its internal controls related to financial reporting and oversight, stemming from the issues leading to the restatement.
- 5The company experienced a decline in earnings from continuing operations before minority interest and income taxes, largely due to significant charges for litigation settlements and asset impairment, along with the impact of working down wholesaler inventories.
- 6Sales for the Pharmaceuticals segment showed a decline, particularly in the U.S., due to generic competition for key products like GLUCOPHAGE®, TAXOL®, and BUSPAR.
- 7The company is actively cooperating with SEC and U.S. Attorney's Office investigations into wholesaler inventory practices and related accounting matters.